The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
Open accessAbstract
BACKGROUND: Interactions between leukocyte-function-associated antigen type 1 (LFA-1) and intercellular adhesion molecules are important in the pathogenesis of psoriasis. Efalizumab, a humanized monoclonal antibody, binds to the alpha subunit (CD11a) of LFA-1 and inhibits the activation of T cells. METHODS: In a phase 3, multicenter, randomized, placebo-controlled, double-blind study, we assign 597 subjects with psoriasis to receive subcutaneous efalizumab (1 or 2 mg per kilogram of body weight per week) or placebo for 12 weeks. Depending on the response after 12 weeks, subjects received an additional 12 weeks of treatment with efalizumab or placebo. Study treatments were discontinued at week 24, and subjects were followed for an additional 12 weeks. RESULTS: At week 12, there was an improvement of 75 percent or more in the psoriasis area-and-severity index in 22 percent of the subjects who had received 1 mg of efalizumab per kilogram per week and 28 percent of those who had received 2 mg of efalizumab per kilogram per week, as compared with 5 percent of the subjects in the placebo group (P<0.001 for both comparisons). Efalizumab-treated subjects had greater improvement than those in the placebo group as early as week 4 (P<0.001). Among the efalizumab-treated subjects who had an improvement of 75 percent or more at week 12, improvement was maintained through week 24 in 77 percent of those who continued to receive efalizumab, as compared with 20 percent of those who were switched to placebo (P<0.001 for both comparisons). After the discontinuation of efalizumab at week 24, an improvement of 50 percent or more in the psoriasis area-and-severity index was maintained in approximately 30 percent of subjects during the 12 weeks of follow-up. Efalizumab was well tolerated, and adverse events were generally mild to moderate. CONCLUSIONS: Efalizumab therapy resulted in significant improvements in plaque psoriasis in subjects with moderate-to-severe disease. Extending treatment from 12 to 24 weeks resulted in both maintenance and improvement of responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Immunological Synapse: A Molecular Machine Controlling T Cell Activation
Grakoui, A., Bromley, S. K., Sumen, C., Davis, M. M., Shaw, A. S., Allen, P. M., & Dustin, M. L. (1999) · Science · doi:10.1126/science.285.5425.221 · Cited by 3,102
Psoriasis causes as much disability as other major medical diseases
Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B., & Reboussin, D. M. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70112-x · Cited by 1,491
Dustin, M. L., & Springer, T. A. (1988) · The Journal of cell biology · doi:10.1083/jcb.107.1.321 · Cited by 985
Psoriasis − epidemiology and clinical spectrum
Christophers, E. (2001) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2001.00832.x · Cited by 972
The immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600
Methotrexate versus Cyclosporine in Moderate-to-Severe Chronic Plaque Psoriasis
Heydendael, V. M. R., Spuls, P. I., Opmeer, B. C., de Borgie, C. A. J. M., Reitsma, J. B., Goldschmidt, W. F. M., Bossuyt, P. M. M., Bos, J. D., & de Rie, M. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021359 · Cited by 475
Sandborn, W. J., & Hanauer, S. B. (1999) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199905000-00008 · Cited by 454
The risk of melanoma in association with long-term exposure to PUVA
Stern, R. S. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.114576 · Cited by 370
Krueger, G. G., Papp, K. A., Stough, D. B., Loven, K. H., Gulliver, W. P., & Ellis, C. N. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.127247 · Cited by 338
Properties of the urn randomization in clinical trials
Wei, L. J., & Lachin, J. M. (1988) · Controlled Clinical Trials · doi:10.1016/0197-2456(88)90048-7 · Cited by 308
Ashcroft, Po, L. W., Williams, & Griffiths (1999) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1999.02963.x · Cited by 287
Immunocompetent cells in psoriasis: In situ immunophenotyping by monoclonal antibodies
Bos, J. D., Hulsebosch, H. J., Krieg, S. R., Bakker, P. M., & Cormane, R. H. (1983) · Archives of Dermatological Research · doi:10.1007/bf00510050 · Cited by 236
Gottlieb, A. B., Krueger, J. G., Wittkowski, K., Dedrick, R., Walicke, P. A., & Garovoy, M. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.5.591 · Cited by 230
Self-citationGottlieb, A., Krueger, J. G., Bright, R., Ling, M., Lebwohl, M., Kang, S., Feldman, S., Spellman, M., Wittkowski, K., Ochs, H. D., et al. (2000) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(00)90214-7 · Cited by 201
Self-citationWerther, W., González, T., O'Connor, S. L., McCabe, S., Chan, B., Hotaling, T. E., Champe, M., Fox, J. A., Jardieu, P. M., Berman, P. W., et al. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4986 · Cited by 148
Long-term Safety of Cyclosporine in the Treatment of Psoriasis
Grossman, R. (1996) · Archives of Dermatology · doi:10.1001/archderm.132.6.623 · Cited by 128
Crandall, W., & Mackner, L. M. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01411.x · Cited by 125
Sandborn, W. J., & Hanauer, S. B. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.3780050209 · Cited by 102
Selective targeting of T cell subsets: focus on alefacept – a remittive therapy for psoriasis
Krueger, G. G. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.4.431 · Cited by 74
Kuypers, T. W., & Ross, D. (1989) · Research in Immunology · doi:10.1016/0923-2494(89)90114-4 · Cited by 45
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., Lebwohl, M., Koo, J. Y. M., Elmets, C. A., Korman, N. J., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.039 · Cited by 1,222
Self-citationEtanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069
Self-citation
Metadata
- Authors
- Lebwohl, M., Tyring, S. K., Hamilton, T. K., Toth, D., Glazer, S., Tawfik, N. H., Walicke, P., Dummer, W., Wang, X., Garovoy, M. R., & Pariser, D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-11-20
- Volume
- 349
- Issue
- 21
- Pages
- 2004-2013
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152976783
- Cited by
- 570
- References
- 20
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.